Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-095777
Filing Date
2024-08-13
Accepted
2024-08-13 08:19:02
Documents
82
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q mreo-20240630.htm   iXBRL 10-Q 1938489
2 EX-31.1 mreo-ex31_1.htm EX-31.1 21615
3 EX-31.2 mreo-ex31_2.htm EX-31.2 21144
4 EX-32.1 mreo-ex32_1.htm EX-32.1 7412
5 EX-32.2 mreo-ex32_2.htm EX-32.2 7163
  Complete submission text file 0000950170-24-095777.txt   9205098

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mreo-20240630.xsd EX-101.SCH 1538630
85 EXTRACTED XBRL INSTANCE DOCUMENT mreo-20240630_htm.xml XML 1616264
Mailing Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON X0 W1G0QF
Business Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON X0 W1G0QF 4403330237300
Mereo BioPharma Group plc (Filer) CIK: 0001719714 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38452 | Film No.: 241198888
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)